| Bioactivity | CZL80, a brain-penetrable caspase-1 inhibitor with an IC50 of 0.01 μM, could be used in the study of febrile seizures and later enhanced epileptogenic susceptibility[1]. |
| In Vivo | CZL80 (7.5 mg/kg, i.v., qod) 显著降低了神经元兴奋性和热性惊厥发作的发生率，并且在成年小鼠中，减轻了后期增强的癫痫易感性[1]。CZL80延迟给药能够有效减轻光栓形成引起的进行性神经功能障碍[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 313482-91-6 |
| Formula | C19H14N2O4S |
| Molar Mass | 366.39 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yangshun Tang, et al. Structure-based discovery of CZL80, a caspase-1 inhibitor with therapeutic potential for febrile seizures and later enhanced epileptogenic susceptibility. Br J Pharmacol. 2020 Aug;177(15):3519-3534. [2]. Ling Pan, et al. Novel Caspase-1 inhibitor CZL80 improves neurological function in mice after progressive ischemic stroke within a long therapeutic time-window. Acta Pharmacol Sin. 2022 Nov;43(11):2817-2827. |